Through in vivo drug screens we have identified drugs that can modulate the iron regulatory hormone, hepcidin.
Testing the efficacy of Proton Pump Inhibitor drugs in reducing iron overload in thalassemia patients
We propose to test the efficacy of proton-pump inhibitor (PPI) drugs in reducing iron overload in Non Transfusion Dependent Thalassemia (NTDT) patients. Enrolled patients would be prescribed a daily dose of 20mg Omeprazole for 18 months.
We invite clinicians and research institutions to participate in this endeavor to re-purpose drugs for reducing iron overload in Thalassemia.
We invite potential collaborators interested in pursuing this clinical study.
For more details, please email at chetana@igib.in
Through in vivo drug screens we have identified drugs that can modulate the iron regulatory hormone, hepcidin.
Chetana Sachidanandan is interested in understanding the mechanisms that operate to develop and maintain a functional liver and in developing new therapeutic interventions to prevent or treat breakdown of these processes. Her lab primarily uses the vertebrate model zebrafish (Danio rerio) to model liver biology.
CSIR-Institute of Genomics & Integrative Biology (IGIB) is a premier Institute of Council of Scientific and Industrial Research (CSIR), engaged in research of national importance in the areas of genomics, molecular medicine, bioinformatics, proteomics and environmental biotechnology.